Biogen Inc. (BIIB)

Biogen's stock price has been impacted by several events over the past six months. The company reported Q4 2025 earnings with adjusted EPS exceeding estimates and issued aggressive guidance for 2026. Biogen announced plans to acquire Apellis and entered into an agreement with TJ Biopharma. The FDA approved a new high-dose regimen of SPINRAZA® for Spinal Muscular Atrophy, and the FDA extended the review period for LEQEMBI IQLIK. Biogen reported its Q1 2026 results, with revenues exceeding analysts' expectations. Analysts have shown constructive sentiment, lifting Biogen's fair value estimate and price targets.

There is no explicit mention or analysis of demand seasonality for Biogen, Inc.'s products and services in the available information.

Biogen Inc. is a multinational biotechnology company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company's major products include treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), and severe plaque psoriasis. Biogen also produces biosimilars and collaborates with other companies on treatments for Alzheimer's disease and Postpartum Depression.

Biogen is headquartered in Cambridge, Massachusetts, United States, which serves as a main innovation hub for R&D, with international headquarters in Baar, Switzerland. The company has a direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. R&D teams are primarily in Cambridge, MA, with an expansion to South San Francisco, CA. Biogen's largest manufacturing campuses are in Wake and Durham counties in North Carolina, and it also has manufacturing facilities in Solothurn, Switzerland.

In the past year, Biogen has focused on strengthening its corporate responsibility and sustainability efforts, publishing its 2023 Corporate Responsibility Report. This included adding four first-in-class medicines to its portfolio and expanding access to SPINRAZA®. Biogen also certified 100% of its labs through My Green Lab and maintained a commitment to 100% renewable electricity across its sites. The company has been actively working to pivot towards new neurodegenerative and rare disease therapies under new leadership after the "Aduhelm" controversy.

Biogen's ownership is primarily dominated by institutional investors, who own approximately 66.94% of the company's stock, with 0.19% by Insiders, and 32.87% by Public Companies and Individual Investors. Major institutional shareholders include Vanguard Group Inc. and BlackRock, Inc., which held approximately 11.4% and 8.7% of outstanding shares, respectively, as of Q1 2025.